Accueil   Diary - News   All news MaaT Pharma Unveils the First GMP-Compliant European Fecal Microbiota Transfer Platform

MaaT Pharma Unveils the First GMP-Compliant European Fecal Microbiota Transfer Platform

Logo MaâT 4e versionMajor treatments such as high-dose antibiotic therapies and chemotherapies can lead to serious complications and create a gut microbiota imbalance (formerly called intestinal flora).

Thanks to the €16M funding round led by multiple venture capitalists, in the last 18 months, MaaT Pharma aims to correct this imbalance.

This biotech company, a specialist in intestinal microbiota, has launched its clinical trials and officially opened its platform for the production of clinical batches on November 3rd, 2016.

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree